Complicating autoimmune diseases in myasthenia gravis: a review

References

• Zhang, B., J. S. Tzartos, M. Belimezi, et al. 2012. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 69: 445–451
   PubMed Web of Science ®Google Scholar
• Gilhus, N. E. 2009. Autoimmune myasthenia gravis. Expert Rev. Neurother. 9: 351–358
   PubMed Web of Science ®Google Scholar
• Keesey, J. C. 2004. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 29: 484–505
   PubMed Web of Science ®Google Scholar
• Grob, D., N. Brunner, T. Namba, and M. Pagala. 2008. Lifetime course of myasthenia gravis. Muscle Nerve. 37: 141–149
   PubMed Web of Science ®Google Scholar
• Jacob, S., S. Viegas, D. Lashley, and D. Hilton-Jones. 2009. Myasthenia gravis and other neuromuscular junction disorders. Pract. Neurol. 9: 364–371
   PubMedGoogle Scholar
• Alkhawajah, N. M., and J. Oger. 2013. Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve. 48: 705–710
   PubMed Web of Science ®Google Scholar
• Aarli, J. A. 2008. Myasthenia gravis in the elderly: is it different? Ann. N. Y. Acad. Sci. 1132: 238–243
   PubMed Web of Science ®Google Scholar
• Fang, F., O. Sveinsson, G. Thormar, et al. 2014. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J. Intern. Med. 277: 594--604
   PubMed Web of Science ®Google Scholar
• Christensen, P. B., T. S. Jensen, I. Tsiropoulos, et al. 1995. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol. Scand. 91: 192–195
   PubMed Web of Science ®Google Scholar
• Sardu, C., E. Cocco, A. Mereu, et al. 2012. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 7: e32487
   PubMedGoogle Scholar
• Tellez-Zenteno, J. F., G. Cardenas, B. Estanol, et al. 2004. Associated conditions in myasthenia gravis: response to thymectomy. Eur. J. Neurol. 11: 767–773
   PubMed Web of Science ®Google Scholar
• Ramagopalan, S. V., C. Anderson, A. D. Sadovnick, and G. C. Ebers. 2007. Genomewide study of multiple sclerosis. N. Engl. J. Med. 357: 2199–2200; author reply 2200-2191
   PubMed Web of Science ®Google Scholar
• Mao, Z. F., L. X. Yang, X. A. Mo, et al. 2011. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int. J. Neurosci. 121: 121–129
   PubMed Web of Science ®Google Scholar
• Jallouli, M., D. Saadoun, B. Eymard, et al. 2012. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J. Neurol. 259: 1290–1297
   PubMed Web of Science ®Google Scholar
• Thorlacius, S., J. A. Aarli, T. Riise, et al. 1989. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol. Scand. 80: 290–295
   PubMed Web of Science ®Google Scholar
• Sthoeger, Z., A. Neiman, D. Elbirt, et al. 2006. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study. Am. J. Med. Sci. 331: 4–9
   PubMed Web of Science ®Google Scholar
• Gilhus, N. E., A. Nacu, J. B. Andersen, and J. F. Owe. 2015. Myasthenia gravis and risks for comorbidity. Eur. J. Neurol. 22: 17–23
   PubMed Web of Science ®Google Scholar
• Gregersen, P. K., R. Kosoy, A. T. Lee, et al. 2012. Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann. Neurol. 72: 927–935
   PubMed Web of Science ®Google Scholar
• Nakamura, H., T. Usa, M. Motomura, et al. 2008. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J. Endocrinol. Invest. 31: 861–865
   PubMed Web of Science ®Google Scholar
• Chen, Y. L., J. H. Yeh, and H. C. Chiu. 2013. Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol. Scand. 127: 170–174
   PubMed Web of Science ®Google Scholar
• Jacobson, D. M. 1995. Acetylcholine receptor antibodies in patients with Graves' ophthalmopathy. J. Neuroophthalmol. 15: 166–170
   PubMed Web of Science ®Google Scholar
• Marino, M., G. Barbesino, A. Pinchera, et al. 2000. Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis. Thyroid. 10: 799–802
   PubMed Web of Science ®Google Scholar
• Kaminski, H. J., Z. Li, C. Richmonds, et al. 2003. Susceptibility of ocular tissues to autoimmune diseases. Ann. N. Y. Acad. Sci. 998: 362–374
   PubMed Web of Science ®Google Scholar
• Yamanaka, K., H. Nakayama, K. Watanabe, and Y. Kameda. 2006. Anterior mediastinal mass in a patient with Graves' disease. Ann. Thorac. Surg. 81: 1904–1906
   PubMed Web of Science ®Google Scholar
• Stefan, M., C. Wei, A. Lombardi, et al. 2014. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc. Natl. Acad. Sci USA. 111: 12562–12567
   PubMed Web of Science ®Google Scholar
• Garlepp, M. J., R. L. Dawkins, F. T. Christiansen, et al. 1981. Autoimmunity in ocular and generalised myasthenia gravis. J. Neuroimmunol. 1: 325–332
   PubMed Web of Science ®Google Scholar
• Mistry, N., J. Wass, and M. R. Turner. 2009. When to consider thyroid dysfunction in the neurology clinic. Pract. Neurol. 9: 145–156
   PubMedGoogle Scholar
• Kanazawa, M., T. Shimohata, K. Tanaka, and M. Nishizawa. 2007. Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur. J. Neurol. 14: 1403–1404
   PubMed Web of Science ®Google Scholar
• Ramanujam, R., F. Piehl, R. Pirskanen, et al. 2011. Concomitant autoimmunity in myasthenia gravis – lack of association with IgA deficiency. J. Neuroimmunol. 236: 118–122
   PubMed Web of Science ®Google Scholar
• Toth, C., D. McDonald, J. Oger, and K. Brownell. 2006. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol. Scand. 114: 124–132
   PubMed Web of Science ®Google Scholar
• Leite, M. I., E. Coutinho, M. Lana-Peixoto, et al. 2012. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 78: 1601–1607
   PubMed Web of Science ®Google Scholar
• Lakhal, K., Y. Blel, M. Fysekidis, et al. 2008. Concurrent Graves disease thyrotoxicosis and myasthenia gravis: the treatment of the former may dangerously reveal the latter. Anaesthesia. 63: 876–879
   PubMed Web of Science ®Google Scholar
• Suzuki, S., M. Shimoda, M. Kawamura, et al. 2005. Myasthenia gravis accompanied by alopecia areata: clinical and immunogenetic aspects. Eur. J. Neurol. 12: 566–570
   PubMed Web of Science ®Google Scholar
• Iyer, A., L. Elsone, R. Appleton, and A. Jacob. 2014. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 47: 154–161
   PubMed Web of Science ®Google Scholar
• Poulas, K., E. Tsibri, A. Kokla, et al. 2001. Epidemiology of seropositive myasthenia gravis in Greece. J. Neurol. Neurosurg. Psychiatry 71: 352–356
   PubMed Web of Science ®Google Scholar
• Viken, M. K., H. D. Sollid, G. Joner, et al. 2007. Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. Hum. Immunol. 68: 748–755
   PubMed Web of Science ®Google Scholar
• Giraud, M., G. Beaurain, A. M. Yamamoto, et al. 2001. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 57: 1555–1560
   PubMed Web of Science ®Google Scholar
• Kraemer, M. H., E. A. Donadi, M. A. Tambascia, et al. 1998. Relationship between HLA antigens and infectious agents in contributing towards the development of Graves' disease. Immunol. Invest. 27: 17–29
   PubMed Web of Science ®Google Scholar
• Barker, J. M., K. J. Barriga, L. Yu, et al.; Diabetes Autoimmunity Study in the Young. 2004. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J. Clin. Endocrinol. Metab. 89: 3896–3902
   PubMed Web of Science ®Google Scholar
• Badrising, U. A., G. M. Schreuder, M. J. Giphart, et al. 2004. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 63: 2396–2398
   PubMed Web of Science ®Google Scholar
• Matsui, N., S. Nakane, Y. Nakagawa, et al. 2009. Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J. Neurol. Neurosurg. Psychiatry 80: 1168–1171
   PubMed Web of Science ®Google Scholar
• Klein, R., A. Marx, P. Strobel, et al. 2013. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum. Immunol. 74: 1184–1193
   PubMed Web of Science ®Google Scholar
• Somnier, F. E., G. O. Skeie, J. A. Aarli, and W. Trojaborg. 1999. EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis. Eur. J. Neurol. 6: 555–563
   PubMed Web of Science ®Google Scholar
• Suzuki, S., K. Utsugisawa, H. Yoshikawa, et al. 2009. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch. Neurol. 66: 1334–1338
   PubMed Web of Science ®Google Scholar
• Cavalcante, P., P. Cufi, R. Mantegazza, et al. 2013. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun. Rev. 12: 863–874
   PubMed Web of Science ®Google Scholar
• Marx, A., F. Pfister, B. Schalke, et al. 2013. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun. Rev. 12: 875–884
   PubMed Web of Science ®Google Scholar
• Holbro, A., A. Jauch, D. Lardinois, et al. 2012. High prevalence of infections and autoimmunity in patients with thymoma. Hum. Immunol. 73: 287–290
   PubMed Web of Science ®Google Scholar
• Levy, Y., A. Afek, Y. Sherer, et al. 1998. Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Semin. Arthritis Rheum. 28: 73–79
   PubMed Web of Science ®Google Scholar
• Marx, A., H. K. Muller-Hermelink, and P. Strobel. 2003. The role of thymomas in the development of myasthenia gravis. Ann. N. Y. Acad. Sci. 998: 223–236
   PubMed Web of Science ®Google Scholar
• Muller-Hermelink, H. K., and A. Marx. 2000. Thymoma. Curr. Opin. Oncol. 12: 426–433
   PubMed Web of Science ®Google Scholar
• Souadjian, J. V., P. Enriquez, M. N. Silverstein, and J. M. Pepin. 1974. The spectrum of diseases associated with thymoma. Coincidence or syndrome? Arch. Intern. Med. 134: 374–379
   PubMed Web of Science ®Google Scholar
• Marino, M., R. Ricciardi, A. Pinchera, et al. 1997. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J. Clin. Endocrinol. Metab. 82: 438–443
   PubMed Web of Science ®Google Scholar
• De Keyzer, K., P. Peeters, C. Verhelst, et al. 2009. Autoimmune haemolytic anaemia associated with a thymoma: case report and review of the literature. Acta Clin. Belg. 64: 447–451
   PubMed Web of Science ®Google Scholar
• Suzuki, S., S. Nogawa, K. Tanaka, et al. 2003. Initial predictors of development of pure red cell aplasia in myasthenia gravis after thymectomy. Clin. Neurol. Neurosurg. 106: 16–18
   PubMed Web of Science ®Google Scholar
• Inada, K., M. Okumura, H. Shiono, et al. 2005. Role of positive selection of thymoma-associated T cells in the pathogenesis of myasthenia gravis. J. Surg. Res. 126: 34–40
   PubMed Web of Science ®Google Scholar
• Yapali, S., N. Oruc, S. Ilgun, et al. 2012. Acute presentation of autoimmune hepatitis in a patient with myasthenia gravis, thymoma, Hashimoto thyroiditis and connective tissue disorder. Hepatol. Res. 42: 835–839
   PubMed Web of Science ®Google Scholar
• Coppede, F., R. Ricciardi, M. Denaro, et al. 2013. Association of the DNMT3B-579G>T polymorphism with risk of thymomas in patients with myasthenia gravis. PLoS One 8: e80846
   PubMedGoogle Scholar
• Suzuki, S., K. Utsugisawa, Y. Nagane, and N. Suzuki. 2011. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis. 2011: 740583
   PubMedGoogle Scholar
• Mygland, A., J. A. Aarli, H. Hofstad, and N. E. Gilhus. 1991. Heart muscle antibodies in myasthenia gravis. Autoimmunity 10: 263–267
   PubMed Web of Science ®Google Scholar
• Suzuki, S., A. Baba, K. Kaida, et al. 2014. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur. J. Neurol. 21: 223–230
   PubMed Web of Science ®Google Scholar
• Rosenstein, E. D., M. J. Zucker, and N. Kramer. 2000. Giant cell myocarditis: most fatal of autoimmune diseases. Semin. Arthritis Rheum. 30: 1–16
   PubMed Web of Science ®Google Scholar
• Suzuki, S., K. Utsugisawa, and N. Suzuki. 2013. Overlooked non-motor symptoms in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry. 84: 989–994
   PubMed Web of Science ®Google Scholar
• Zonana, M. F., E. Reyes, and A. K. Weisman. 2002. Coexistence of four autoimmune diseases in one patient: the kaleidoscope of autoimmunity. J. Clin. Rheumatol. 8: 322–325
   PubMed Web of Science ®Google Scholar
• Ratanakorn, D., and A. Vejjajiva. 2002. Long-term follow-up of myasthenia gravis patients with hyperthyroidism. Acta Neurol. Scand. 106: 93–98
   PubMed Web of Science ®Google Scholar
• Mevorach, D., S. Perrot, N. M. Buchanan, et al. 1995. Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature. Lupus 4: 33–37
   PubMed Web of Science ®Google Scholar
• Gerli, R., R. Paganelli, A. Cossarizza, et al. 1999. Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J Allergy Clin. Immunol. 103: 865–872
   PubMed Web of Science ®Google Scholar
• Kondo, K., and Y. Monden. 2005. Myasthenia gravis appearing after thymectomy for thymoma. Eur. J. Cardiothorac. Surg. 28: 22–25
   PubMed Web of Science ®Google Scholar
• Verschuuren, J. J., M. G. Huijbers, J. J. Plomp, et al. 2013. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun. Rev. 12: 918–923
   PubMed Web of Science ®Google Scholar
• Evoli, A., P. A. Tonali, L. Padua, et al. 2003. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 126: 2304–2311
   PubMed Web of Science ®Google Scholar
• Verschuuren, J. J., J. Palace, and N. E. Gilhus. 2010. Clinical aspects of myasthenia explained. Autoimmunity 43: 344–352
   PubMed Web of Science ®Google Scholar
• Vincent, A., M. I. Leite, M. E. Farrugia, et al. 2008. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann. N. Y. Acad. Sci. 1132: 84–92
   PubMed Web of Science ®Google Scholar
• McConville, J., M. E. Farrugia, D. Beeson, et al. 2004. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55: 580–584
   PubMed Web of Science ®Google Scholar
• Niks, E. H., J. B. Kuks, B. O. Roep, et al. 2006. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology. 66: 1772–1774
   PubMed Web of Science ®Google Scholar
• Niks, E. H., J. B. Kuks, and J. J. Verschuuren. 2007. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J. Neurol. Neurosurg. Psychiatry. 78: 417–418
   PubMed Web of Science ®Google Scholar
• Tron, F., D. Gilbert, H. Mouquet, et al. 2005. Genetic factors in pemphigus. J. Autoimmun. 24: 319–328
   PubMed Web of Science ®Google Scholar
• Sylvester, J., G. Purdie, M. Slee, et al. 2013. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review. J. Neuroimmunol. 264: 130–133
   PubMed Web of Science ®Google Scholar
• Horvath, B., J. Huizinga, H. H. Pas, et al. 2012. Low-dose rituximab is effective in pemphigus. Br. J. Dermatol. 166: 405–412
   PubMed Web of Science ®Google Scholar
• Diaz-Manera, J., R. Rojas-Garcia, E. Gallardo, et al. 2007. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat. Clin. Pract. Neurol. 3: 405–410
   PubMedGoogle Scholar
• Saulat, B., P. Maertens, W. J. Hamilton, and B. A. Bassam. 2007. Anti-musk antibody after thymectomy in a previously seropositive myasthenic child. Neurology 69: 803–804
   PubMed Web of Science ®Google Scholar
• Sanders, D. B., and V. C. Juel. 2008. MuSK-antibody positive myasthenia gravis: questions from the clinic. J. Neuroimmunol. 201–202: 85–89
   PubMed Web of Science ®Google Scholar
• Kostera-Pruszczyk, A., and H. Kwiecinski. 2009. Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy. J. Neurol. 256: 1780–1781
   PubMed Web of Science ®Google Scholar
• Rajakulendran, S., S. Viegas, J. Spillane, and R. S. Howard. 2012. Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies. J. Neurol. 259: 2736–2739
   PubMed Web of Science ®Google Scholar
• Poulas, K., E. Koutsouraki, G. Kordas, et al. 2012. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J. Neuroimmunol. 250: 94–98
   PubMed Web of Science ®Google Scholar
• Pevzner, A., B. Schoser, K. Peters, et al. 2012. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 259: 427–435
   PubMed Web of Science ®Google Scholar
• Higuchi, O., J. Hamuro, M. Motomura, and Y. Yamanashi. 2011. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69: 418–422
   PubMed Web of Science ®Google Scholar
• Tsivgoulis, G., G. Dervenoulas, S. J. Tzartos, et al. 2014. Double seropositive myasthenia gravis with acetylcholine receptor and lipoprotein receptor-related protein 4 antibodies. Muscle Nerve 49: 930–931
   PubMed Web of Science ®Google Scholar
• Guptill, J. T., and D. B. Sanders. 2010. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr. Opin. Neurol. 23:530–535
   PubMed Web of Science ®Google Scholar
• Zisimopoulou, P., P. Evangelakou, J. Tzartos, et al. 2014. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J. Autoimmun. 52: 139–145
   PubMed Web of Science ®Google Scholar
• Davidson, A., and B. Diamond. 2001. Autoimmune diseases. N. Engl. J. Med. 345: 340–350
   PubMed Web of Science ®Google Scholar
• Waterfield, M., and M. S. Anderson. 2010. Clues to immune tolerance: the monogenic autoimmune syndromes. Ann. N. Y. Acad. Sci. 1214: 138–155
   PubMed Web of Science ®Google Scholar
• Bach, J. F. 2012. The etiology of autoimmune diseases: the case of myasthenia gravis. Ann. N. Y. Acad. Sci. 1274: 33–39
   PubMed Web of Science ®Google Scholar
• Avidan, N., R. Le Panse, S. Berrih-Aknin, and A. Miller. 2014. Genetic basis of myasthenia gravis – a comprehensive review. J. Autoimmun. 52: 146–153
   PubMed Web of Science ®Google Scholar
• Zhernakova, A., S. Withoff, and C. Wijmenga. 2013. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat. Rev. Endocrinol. 9: 646–659
   PubMed Web of Science ®Google Scholar
• Mangalam, A. K., G. Rajagopalan, V. Taneja, and C. S. David. 2008. HLA class II transgenic mice mimic human inflammatory diseases. Adv. Immunol. 97: 65–147
   PubMed Web of Science ®Google Scholar
• Liu, X., W. Tian, L. Li, and J. Cai. 2011. Characterization of the major histocompatibility complex class I chain-related gene B (MICB) polymorphism in a northern Chinese Han population: the identification of a new MICB allele, MICB*023. Hum. Immunol. 72: 727–732
   PubMed Web of Science ®Google Scholar
• Franciotta, D., M. Cuccia, E. Dondi, et al. 2001. Polymorphic markers in MHC class II/III region: a study on Italian patients with myasthenia gravis. J. Neurol. Sci. 190: 11–16
   PubMed Web of Science ®Google Scholar
• Cho, J. H., and P. K. Gregersen. 2011. Genomics and the multifactorial nature of human autoimmune disease. N. Engl. J. Med. 365: 1612–1623
   PubMed Web of Science ®Google Scholar
• Adrianto, I., S. Wang, G. B. Wiley, et al. 2012. Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum. 64: 3695–3705
   PubMed Web of Science ®Google Scholar
• Lessard, C. J., H. Li, I. Adrianto, et al. 2013. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat. Genet. 45: 1284–1292
   PubMed Web of Science ®Google Scholar
• Ramirez, V. P., I. Gurevich, and B. J. Aneskievich. 2012. Emerging roles for TNIP1 in regulating post-receptor signaling. Cytokine Growth Factor Rev. 23: 109–118
   PubMed Web of Science ®Google Scholar
• Maniaol, A. H., A. Elsais, A. R. Lorentzen, et al. 2012. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 7: e36603
   PubMed Web of Science ®Google Scholar
• Testi, M., C. Terracciano, A. Guagnano, et al. 2012. Association of HLA-DQB1 *05:02 and DRB1 *16 alleles with late-onset, nonthymomatous, AChR-Ab-positive myasthenia gravis. Autoimmune Dis. 2012: 541760
   PubMedGoogle Scholar
• Alahgholi-Hajibehzad, M., V. Yilmaz, Y. Gulsen-Parman, et al. 2013. Association of HLA-DRB1 *14, -DRB1 *16 and -DQB1 *05 with MuSK-myasthenia gravis in patients from Turkey. Hum. Immunol. 74: 1633–1635
   PubMed Web of Science ®Google Scholar
• Bartoccioni, E., F. Scuderi, A. Augugliaro, et al. 2009. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72: 195–197
   PubMed Web of Science ®Google Scholar
• Zhu, W. H., J. H. Lu, J. Lin, et al. 2012. HLA-DQA1*03:02/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese. J. Neuroimmunol. 247: 81–85
   PubMed Web of Science ®Google Scholar
• Vandiedonck, C., C. Capdevielle, M. Giraud, et al. 2006. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann. Neurol. 59: 404–407
   PubMed Web of Science ®Google Scholar
• Chuang, W. Y., P. Strobel, D. Belharazem, et al. 2009. The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes Immun. 10: 667–672
   PubMed Web of Science ®Google Scholar
• Kaya, G. A., A. N. Coskun, V. Yilmaz, et al. 2014. The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey. PLoS One 9: e104760
   PubMedGoogle Scholar
• Giraud, M., R. Taubert, C. Vandiedonck, et al. 2007. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 448: 934–937
   PubMed Web of Science ®Google Scholar
• Strobel, P., W. Y. Chuang, S. Chuvpilo, et al. 2008. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann. N. Y. Acad. Sci. 1132: 143–156
   PubMed Web of Science ®Google Scholar
• Wang, X. B., R. Pirskanen, R. Giscombe, and A. K. Lefvert. 2008. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J. Intern. Med. 263: 61–69
   PubMed Web of Science ®Google Scholar
• Gu, M., M. Kakoulidou, R. Giscombe, et al. 2008. Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. Clin. Immunol. 128: 374–381
   PubMed Web of Science ®Google Scholar
• Smyth, D. J., V. Plagnol, N. M. Walker, et al. 2008. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med. 359: 2767–2777
   PubMed Web of Science ®Google Scholar
• Kurko, J., T. Besenyei, J. Laki, et al. 2013. Genetics of rheumatoid arthritis – a comprehensive review. Clin. Rev. Allergy Immunol. 45: 170–179
   PubMed Web of Science ®Google Scholar
• Ploski, R., K. Szymanski, and T. Bednarczuk. 2011. The genetic basis of graves' disease. Curr. Genomics 12: 542–563
   PubMed Web of Science ®Google Scholar